JP2022516469A5 - - Google Patents

Info

Publication number
JP2022516469A5
JP2022516469A5 JP2021537781A JP2021537781A JP2022516469A5 JP 2022516469 A5 JP2022516469 A5 JP 2022516469A5 JP 2021537781 A JP2021537781 A JP 2021537781A JP 2021537781 A JP2021537781 A JP 2021537781A JP 2022516469 A5 JP2022516469 A5 JP 2022516469A5
Authority
JP
Japan
Prior art keywords
alkyl
nitrogen
sulfur
oxygen
heteroatoms selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021537781A
Other languages
English (en)
Japanese (ja)
Other versions
JP7553450B2 (ja
JP2022516469A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/068648 external-priority patent/WO2020139988A1/en
Publication of JP2022516469A publication Critical patent/JP2022516469A/ja
Publication of JP2022516469A5 publication Critical patent/JP2022516469A5/ja
Application granted granted Critical
Publication of JP7553450B2 publication Critical patent/JP7553450B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021537781A 2018-12-28 2019-12-27 ユビキチン特異的プロテアーゼ1を阻害するための組成物 Active JP7553450B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862785733P 2018-12-28 2018-12-28
US62/785,733 2018-12-28
PCT/US2019/068648 WO2020139988A1 (en) 2018-12-28 2019-12-27 Compositions for inhibiting ubiquitin specific protease 1

Publications (3)

Publication Number Publication Date
JP2022516469A JP2022516469A (ja) 2022-02-28
JP2022516469A5 true JP2022516469A5 (cg-RX-API-DMAC7.html) 2022-12-22
JP7553450B2 JP7553450B2 (ja) 2024-09-18

Family

ID=71126375

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021537781A Active JP7553450B2 (ja) 2018-12-28 2019-12-27 ユビキチン特異的プロテアーゼ1を阻害するための組成物

Country Status (5)

Country Link
US (1) US20220073525A1 (cg-RX-API-DMAC7.html)
EP (1) EP3902802A4 (cg-RX-API-DMAC7.html)
JP (1) JP7553450B2 (cg-RX-API-DMAC7.html)
CN (1) CN113474346B (cg-RX-API-DMAC7.html)
WO (1) WO2020139988A1 (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114702495A (zh) 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮
EP4291559A1 (en) * 2021-02-15 2023-12-20 Tango Therapeutics, Inc. Pyrrolo[3,2-d]pyrimidine compounds and methods of use in the treatment of cancer
AU2022254062A1 (en) * 2021-04-07 2023-10-12 Forma Therapeutics, Inc. Inhibiting ubiquitin-specific protease 1 (usp1)
US20240226107A1 (en) * 2021-04-09 2024-07-11 Simcere Zaiming Pharmaceutical Co., Ltd. Ubiquitin-specific protease 1 (usp1) inhibitor
JP7746406B2 (ja) * 2021-04-21 2025-09-30 長春金賽薬業有限責任公司 イミダゾール含有縮合環系誘導体、その調製方法及びその医薬上の応用
CN117412973B (zh) * 2021-05-31 2026-07-17 上海瑛派药业有限公司 含氮稠合杂芳双环化合物作为usp1抑制剂及其应用
JP2024540921A (ja) * 2021-10-19 2024-11-06 上海瑛派▲薬▼▲業▼有限公司 Usp1阻害剤としての置換トリアゾロヘテロアリール化合物及びその応用
KR20240117556A (ko) * 2021-11-12 2024-08-01 인실리코 메디신 아이피 리미티드 유비퀴틴 특이적 프로테아제 1(usp1)의 소분자 억제제 및 이의 용도
US20250163049A1 (en) * 2022-02-03 2025-05-22 Exelixis, Inc. Fused bicyclic heterocyclyl compounds as usp1 inhibitors
IL316542A (en) * 2022-04-29 2024-12-01 Jiangsu Yahong Meditech Co Ltd Pyrimidine compound, method for its preparation, and pharmaceutical use thereof
US20240092779A1 (en) * 2022-06-29 2024-03-21 Zentaur Therapeutics Usa Inc. Usp1 inhibitors and uses thereof
WO2024022519A1 (zh) * 2022-07-28 2024-02-01 先声再明医药有限公司 杂环并嘧啶类化合物及其应用
WO2024041634A1 (zh) * 2022-08-26 2024-02-29 先声再明医药有限公司 三环类化合物及其应用
WO2024078436A1 (zh) * 2022-10-09 2024-04-18 海南先声再明医药股份有限公司 杂环并嘧啶类化合物、药物组合物及其应用
EP4605391A1 (en) 2022-10-21 2025-08-27 Exelixis, Inc. 4,5,6,7-tetrahydro-1-pyrazolo[4,3-c]pyridine compounds and derivatives as usp1 inhibitors
WO2024153250A1 (zh) * 2023-01-20 2024-07-25 杭州英创医药科技有限公司 作为usp1抑制剂的化合物
TW202509030A (zh) 2023-05-08 2025-03-01 美商譚格醫療公司 化合物及使用方法
WO2024233665A1 (en) 2023-05-08 2024-11-14 Tango Therapeutics, Inc. Compounds and their use against cancer
TW202446379A (zh) * 2023-05-18 2024-12-01 香港商英矽智能科技知識產權有限公司 泛素特異性蛋白酶1(usp1)之小分子抑制劑及其用途
EP4739397A1 (en) 2023-07-06 2026-05-13 Exelixis, Inc. Fused pyrazole derivatives as usp1 inhibitors
CN119930632B (zh) * 2023-11-06 2025-11-18 中国医学科学院药物研究所 一种三并环类泛素特异性蛋白酶1抑制剂及其制备方法、用途和药物组合物
CN119930633B (zh) * 2023-11-06 2025-11-18 中国医学科学院药物研究所 一种吡咯并蝶啶酮类泛素特异性蛋白酶1抑制剂及其制备方法、用途和药物组合物
AU2024378865A1 (en) 2023-11-10 2026-06-25 Vrise Therapeutics, Inc. Novel molecules as inhibitors of dna damage repair pathway
WO2025151705A1 (en) 2024-01-10 2025-07-17 Vrise Therapeutics, Inc. Novel inhibitors of dna damage repair pathway

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993012113A1 (en) * 1991-12-17 1993-06-24 The Upjohn Company 3-SUBSTITUTED IMIDAZO (1,5-a) AND IMIDAZO (1,5-a)-TRIAZOLO (1,5-c) QUINOXALINES AND QUINAZOLINES WITH CNS ACTIVITY
EA201000046A1 (ru) * 2007-06-21 2011-02-28 Кара Терапеутикс, Инк. Замещенные имидазогетероциклы
MX2011002581A (es) * 2008-09-16 2011-04-07 Proximagen Ltd Compuestos nuevos i.
CN101824036A (zh) * 2009-03-05 2010-09-08 上海恒瑞医药有限公司 四氢咪唑并[1,5-a]吡嗪衍生物的盐,其制备方法及其在医药上的应用
CN114702495A (zh) * 2015-11-20 2022-07-05 福马治疗有限公司 作为泛素-特异性蛋白酶1抑制剂的嘌呤酮

Similar Documents

Publication Publication Date Title
JP2021513534A5 (cg-RX-API-DMAC7.html)
JP2022501354A5 (cg-RX-API-DMAC7.html)
RU2020123151A (ru) Антагонисты tlr7/8 и их применение
RU2017111200A (ru) Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака
PE20230376A1 (es) Compuestos moduladores de la diacilglicerol quinasa
JP2021532109A5 (cg-RX-API-DMAC7.html)
JP2019527718A5 (cg-RX-API-DMAC7.html)
RU2350605C2 (ru) Аналоги хиназолина в качестве ингибиторов рецепторных тирозинкиназ
PE20190806A1 (es) Agonistas heterociclicos del receptor de apelina (apj) y usos de los mismos
JP2016520063A5 (cg-RX-API-DMAC7.html)
JP2014511892A5 (cg-RX-API-DMAC7.html)
JP2015520769A5 (cg-RX-API-DMAC7.html)
JP2023553835A5 (cg-RX-API-DMAC7.html)
JP2016526024A5 (cg-RX-API-DMAC7.html)
JP2021535112A5 (cg-RX-API-DMAC7.html)
JP2012526728A5 (cg-RX-API-DMAC7.html)
JP2018527301A5 (ja) アジリジン含有dnaアルキル化剤
AR048315A1 (es) Compuestos heterociclicos inhibidores de la produccion de citocinas; composiciones farmaceuticas que los contienen y su uso en el tratamiento de enfermedades inflamatorias y oncologicas.
PE131699A1 (es) Inhibidores de aminotiazol de cinasas dependientes de ciclina
RU2013108348A (ru) Конденсированные гетероарилы и их применение
AR043367A2 (es) Derivados de benzofenona, composiciones farmaceuticas y procesos de preparacion.
SI3024819T1 (en) Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B
JP2009536620A5 (cg-RX-API-DMAC7.html)
JP2014511891A5 (cg-RX-API-DMAC7.html)
JP2022511477A5 (cg-RX-API-DMAC7.html)